samedan logo
 
 
 
spacer
home > ebr > summer 2008 > partners for life
PUBLICATIONS
European Biopharmaceutical Review

Partners for Life

Coming from a much respected industry that works hard and invests a lot of money in the development of new treatments that will save or improve lives, it is always frustrating to see that this good work and progress does not necessarily translate into increased share value. One can keep complaining that there is not enough money available to succeed in Europe – that investors don’t support the biotech industry enough. The reality is that success and money will only come if biotech transforms its business model in order to meet investors’ legitimate expectations of getting a reasonable return in a reasonable timeframe.

Is this timeframe compatible with pharmaceutical development timelines? How can we make it compatible so that money starts pouring into our industry again? Consolidation and rapid build-up appear to be the answers for creating shareholder value rapidly. Yes, there is a future for mid-sized companies provided they combine the strengths from both traditional pharma companies, and the entrepreneurial culture of biotech companies and invest in R&D.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Sandrine Cailleteau heads the healthcare practice of Michel Dyens & Co, an independent investment banking firm with offices in Paris, London and NY, providing global M&A advisory. She brings more than 20 years’ industry experience in strategic planning, M&A and licensing in France, the US and Switzerland in her previous roles as CBO of Plethora Solutions; Head of Global Business Development and Licensing at Laboratoires Fournier/Solvay; consultant to Institut Pasteur start-up companies; Director of Strategic Planning and Partnerships at Hesperion/Actelion; and various managing positions with Sanofi/Sanofi-Synthelabo, including Licensing Director and M&A Director. She is also a non-executive Director of Trophos.
spacer
Sandrine Cailleteau
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

airea - The Airport Region in Central Germany

Leipzig/Halle Airport joins forces to attract investors - the aiport and development agencies sign a cooperation agreement covering more than one federal state.
More info >>

White Papers

Outsourcing and Insourcing: How Eurofins solves the bio/pharma industry’s challenges associated with meeting drug development timelines and budgets with restricted headcounts

Eurofins BioPharma Product Testing

Pharmaceutical and biopharmaceutical companies face a significant challenge to get their drug products developed and launched quickly, all while keeping development costs down. One of the most common ways for companies to lower development costs is to manage fixed headcounts. But when the same scope of work still needs to be completed by a designated time with fewer staff members, this presents a significant challenge. So, how do bio/pharma companies solve this ever so common challenge of increasing output while decreasing headcount? There are essentially three options: temporary staffing, outsourcing, or insourcing.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement